Ascletis’ ASC30 Cuts HbA1c by Up to 1.7% Versus Placebo in Phase II Trial
Ascletis said its ASC30 diabetes drug cut HbA1c by up to 1.7% versus placebo in a Phase II trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.